Compare Abeona Therapeutics Inc (ABEO) vs Norfolk Southern Corporation (NSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Norfolk Southern Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while Norfolk Southern Corporation trades at $319.54 (market cap $72.49B). The key difference: Norfolk Southern Corporation is far larger — about 194.2× Abeona Therapeutics Inc's market cap, and Norfolk Southern Corporation pays a 1.67% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NSC | |
|---|---|---|
Market Cap | $373.32M | $72.49B |
Sector | Health | Technology |
52-Week High | $7.23 | $325.68 |
52-Week Low | $4.17 | $259.49 |
Enterprise Value | $228.22M | $88.25B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Norfolk Southern (NSC) trades at $321.9, down 0.25% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $337. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights the ongoing merger process with Union Pacific, a key regulatory and operational focus.
The outlook for NSC is cautiously optimistic, with potential upside from the merger and consistent earnings performance, but risks include regulatory hurdles for the merger and rich valuation multiples. Investors should weigh the strong cash flow generation against execution risks in a consolidating industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →
